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Abstract
Postpartum haemorrhage (PPH) is one of the most important causes of maternal mortality in developing countries. A consensus 
was reached on active management of the third stage of labour for all parturients especially for those for whom the access to 
hospital services is difficult or time-consuming. Oral (methyl)ergometrine was considered to be a possible alternative prophylactic 
oxytocic, that was easy to administer and suitable to be used in developing countries. A research project was set up to investigate 
its suitability to be used for active management of the third stage of labour. It was examined on its stability under tropical 
conditions; on its pharmacokinetic and pharmacodynamic properties and on its clinical effect on the am ount of bloodless after 
childbirth. Oral (methyl)ergometrine is unstable even when stored after refrigerated conditions. Its pharmacokinetic and dynamic 
properties are unpredictable and no clinical effect on reduction of bloodloss after childbirth has been shown. To ameliorate a 
product’s stability seems unlogical, if the same product shows unfavourable pharmacokinetics. All the more so, since the tablets 
do not show the wanted clinical effects. Oral (methyl)ergometrine is not an alternative to parenteral prophylactic oxytocic drugs 
in the active management of the third stage of labour.
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1. Introduction
1.1. Maternal mortality
Every four hours, day in, day out, a  jumbo jet crashes and 
all on board are killed, The 250 passengers are all women. 
They are all either pregnant or have recently given birth to 
a child.
This shocking statement was given by Malcolm Potts 
at the World Health Organization’s (WHO) interre­
gional Meeting on the prevention of maternal mortality, 
November 1985 [1]. This statement is all the more 
intolerable because most of these deaths are theoretically 
preventable with present knowledge and equipment.
Worldwide at least half a million women die annually 
from causes related to pregnancy and childbirth. All but 
6000 occur in developing countries, where 86% of the 
world’s births take place [2]. It shows the poignant
* Corresponding author. Tel.: +31 24 3614726; fax: +31 24
3541194.
inequality in maternal health between the rich and the 
poor* One of the most important causes of maternal 
mortalility is obstetric haemorrhage, claiming 150000 
lives annually [3].
L2. Postpartum haemorrhage
Postpartum haemorrhage (PPH), defined by the 
WHO [2] as postpartum bloodloss ;> 500 ml is a clinical 
diagnosis that encompasses excessive bloodloss after 
delivery and, if untreated, may result in shock and death 
of the mother. The choice of 500 ml is arbitrary but is 
a loss that most mothers can tolerate without risk. In 
countries where many women have severe anaemia, 
maternal bloodloss of even 250 ml may be fatal [4]. 
Another reason for the 500 ml criterion is that bloodloss 
is often underestimated: accurately measured loss is 
usually about twice the estimated loss.
The clinical consequences of postpartum bloodloss 
depend on both the amount and rate of bloodloss and 
whether the mother's health is good, a factor partly 
included in the definition of PPH.
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1.3. Primary prevention o f  PPH
Primary prevention includes the prophylactic treat­
ment of those women at high risk for PPH. However, 
women at low risk for PPH are not excluded from 
excessive loss of blood after delivery. If a woman’s 
immediate referral to hospital is logistically impractica­
ble, as is the case in many third world countries, 
preventive measures against PPH are required for all 
women, not only for those at high risk for PPH. 
Therefore, primary prevention of PPH is advocated at 
all levels of obstetric care.
Primary prevention of PPH implies active manage­
ment of the third stage of labour. Active management 
includes use of an oxytocic, early cord clamping, and 
active expulsion of the placenta. The oxytocic drug of 
choice is oxytocin, 10 IU, given intramuscularly [5].
Evidence for the effectiveness of active management 
of the third stage in women at low risk for PPH is still 
not conclusive. Whether women delivering at home 
with easy accessibility to hospital or those at low risk 
delivering in hospital should have active management 
of the third stage of labour remains controversial and 
awaits support until a clinical trial in this particular 
group of women has shown the effectiveness of active 
management (a modification on the WHO-consensus, 
1989 [6]). Guidelines for clinical practice are shown in 
the flow chart (Fig. 1).
I A. WHO-consensus: active management o f  third stage 
for all [6]
A Technical Working Group on the prevention and 
management of postpartum haemorrhage was convened 
by WHO in Geneva, 3 -6  July 1989, A consensus was 
reached on primary preventive measurements of PPH 
for all parturients, consisting of active management of 
the third stage of labour in particular for those with a 
difficult or time-consuming access to hospital services. 
This implies active management of the third stage of
Fig. L Flowchart illustrating guidelines for clinical practice of post­
partum haemorrhage.
labour. It is also being recommended at the first, most 
peripheral, levels of obstetric care which have difficult 
access to hospital services.
The major drawback was to find a prophylactic 
oxytocic that was easy to administer and stable [6]. 
During the working group, one of the midwives, Bar­
bara Kwast, suggested giving oral ergometrine. From 
that day on the project on oral ergometrine was ini­
tiated.
2. Study design
2.1. Oral (methyl)ergome trine as an easy alternative for 
oxytocin intramuscularly in active management o f  the 
third stage o f  labour ?
The research project consisted of three studies, ori­
ented toward the following questions:
-  Is oral (methyl)ergometrine in contrast to intra­
venous (methyl)ergometrine stable under tropical 
conditions? (Stability study)
-  Are the pharmacokinetic and pharmacodynamic 
properties of (methyl)ergometrine tablets favourable 
enough for use in the third stage of labour? (Phar­
macological study)
-  Do ergometrine tablets have a clinical effect on 
bloodloss after childbirth, in spite of the answers on 
the questions mentioned above? (Clinical trial)
The three questions are related, but were answered
independently. Assuming that the pharmacological 
study and clinical trial would lead to positive results, 
the stability study was started first as there was doubt 
about the stability of the tablets under tropical condi­
tions. While this stability study was being set up and 
started, the pharmacological and clinical parts of the 
project were started simultaneously. This set up of the 
research project had been chosen to underline the three­
fold question, each related to the completely different 
grounds for which an answer had to be given before an 
answer could be given to the principle question: “Is oral 
(methyl)ergometrine a suitable alternative prophylactic 
drug to prevent postpartum haemorrhage?” . Such an 
approach to the question would also detect which as­
pect (stability, pharmacological or clinical) needs ame­
lioration.
3. Results
3A. Stability under simulated tropical conditions [7f8]
The stability of oral preparations of the two er­
gometrine compounds methylergometrine and er­
gometrine under tropical conditions was unknown. 
Stability is defined as the ability of a drug to retain its
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active ingredient (% of stated amount)
time (weeks)
Fig. 2 . Stability of oral ergometrine and methylergometrine exposed 
to least (D6/83) and most (D40/75) extreme conditions; E, er­
gometrine; ME, methylergometrine; D6/83, 6°C, 83% relative humid­
ity (RH) and darkness; D40/75, 40°C, 75% RH and darkness.
properties within specified limits throughout its shelf- 
life. For (methyl)er g ometrine the active ingredient 
should be in between 90 and 110% of the stated 
amount. Shelf-life is the period of time during which 
a drug product is expected, if stored correctly, to re­
main within specifications as determined by stability 
studies. The shelf-life is vised to establish the expiry 
date of each batch.
The ‘shelf lives’ of ergometrine and methyler­
gometrine tablets were examined by exposing these to 
seven artificially controlled conditions. Samples were 
analyzed by high performance liquid chromatography 
(HPLC) at nine different sampling times over a period 
of 1 year to determine the content of ergometrine and 
methylergometrine. Under refrigerated storage (dark 
6°C/83% relative humidity; D6/83), less than 90% of 
the stated amount of active ingredient was found in 
the ergometrine tablets after 14 weeks and in methy­
lergometrine tablets after 21 weeks. When stored in 
the dark at 40°C with 75% relative humidity (D40/75), 
the tablets fell below accepted specification criteria 
(90-110% of stated amount of active ingredient) 
within 3 weeks for ergometrine and 21 weeks for the 
coated methylergometrine tablets (Fig. 2).
The stability of uncoated ergometrine was far less 
than that of coated methylergometrine tablets. Insta­
bility worsened under extreme humid and hot condi­
tions, for both ergometrine and methylergometrine, 
From week 31 onwards, the coating did not seem to 
protect the compound anymore, irrespective of the 
condition of exposure.
Tropical conditions make the tablets unstable with 
humidity as the main adverse factor. Under all simu­
lated conditions, both ergometrine and methyler­
gometrine tablets were unstable.
3.2. Pharmacokinetics and bio availability
Ergometrine and methylergometrine belong to the 
group of oxytocic drugs which enhance uterine motil­
ity. As mentioned earlier prophylactic use of such 
drugs in the third stage of labour reduces the risk of 
PPH and the need for further oxytocic therapy in the 
puerperium. Because pharmacokinetic data for er­
gometrine and methylergometrine were scarce [9,10] 
and mainly concerned methylergometrine [1 1 , 12], male 
volunteers were first studied to determine the pharma­
cokinetics for the oral administration of ergometrine. 
As the pharmacokinetic data of ergometrine in male 
volunteers showed a large variation in bioavailability
[13], a comparable study was performed for methyler­
gometrine in both men and (non-pregnant) women to 
investigate and compare the results with the previous 
data. Thus, three series of experiments were per­
formed.
The aim of these experiments was to assess the 
pharmacokinetics and bioavailability of comparable 
doses methylergometrine and ergometrine (parallel de­
sign) in six male volunteers after an intravenous dose 
and an oral dose of the maleate (cross-over design)
[14]. Further, the pharmacokinetics and bioavailability 
of methylergometrine in six non-pregnant women were 
assessed and compared with the methylergometrine 
values in men (parallel design in gender) [15].
Fig. 3 shows the methylergometrine plasma concen­
trations (ng/ml) versus time after intravenous and oral 
administrations in one representative male volunteer. 
After intravenous administration, the pharmacokinetic 
profile of methylergometrine can be described by a 
two-compartment model. After oral administration, the 
pharmacokinetic profile can be described with a one- 
compartment model. After oral administration the 
compound is rapidly absorbed after a lag time of 10 
min. A maximum plasma concentration of 0.67 ng 
m l - 1  was reached after 24 min and the half-life (2.7 
h) was not significantly different from the half-life 
after intravenous administration (2.31 h).
Table 1 gives the mean pharmacokinetic parameters
4
of methylergometrine maleate after intravenous and 
oral administrations in six male volunteers. This 
shows an extreme interindividual variation in 
bioavailability (and T [/2ahs). The same interindividual
\
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Fig. 3. Methylergometrine plasma concentrations (ng/ml) versus time 
curves after oral administration of 0.125 mg methylergometrine 
maleate (0.095 mg free base) and after intravenous administration of 
0.200 mg methylergometrine maleate (0.152 mg free base) in one 
representative male subject p.o., per os; i.v., intravenous.
variation was shown in experiments with methyler­
gometrine in non-pregnant women [15] and with er- 
gome trine in men [13].
The experiments with oral administrations for both 
men and women show a large inter-individual variabil­
ity in bioavailability. From a pharmacokinetic point of 
view, the oral route of administration does not seem the 
most reliable way for accurate dosing to prevent post­
partum haemorrhage.
Table 1
Mean pharmacokinetic parameters of methylergometrine after an 
intravenous and oral dose of methylergometrine in six male volun­
teers {n =  6)
Intravenous Oral %CV P
Dose (jig) 152 95
T W  (h) 1.85 (0.28) 2.08 (0.43) 0.31
CL (I/h) 32.2 (11.8) 31.1 (10.3) 0.50
K*(l) 71.5 (25.9) 94.4 (38.9) 0.11
Bioavailability (%) 84.9 (37.2) 44
T\/2 abs (h) 0.08 (0.08) 100
MAT 0.87 (0.72) 83
7 ^ ,  lag-time; 7'1y2/9 (h), the half-life o f elimination, calculated by 
Ieast-square linear regression analysis; CL (1/h), total body clear­
ance =  Dose/AUC0_^; Vss (L), the volume of distribution in steady 
state (Kss-D o s e . A U M C o-^ /A U C j^ ); Bioavailability, AUC0_ 
ral.Doseiv/AUC.Doseoral; Txf2 abS (h), the half-life o f absorption, 
calculated by least-square linear regression analysis; MRT, the mean 
residence time AUM C/AUC after oral administration; MAT, the 
mean absorption time (MRTpo — T]ag)
3.3. Pharmacodynamics [16]
The objective was to study the pharmacodynamic 
and pharmacokinetic effect of oral and intravenous 
methylergometrine upon uterine motility during men­
struation. Intra-uterine pressure (IUP) was measured in 
six volunteers with a fluid-filled sponge-tipped catheter 
during menstruation. Methylergometrine maleate was 
given orally (0.5 mg) or intravenously (0.2 mg) in a 
cross-over design.
After intravenous administration, a fast increase of 
the frequency of uterine contractions and basal tone 
occurred with a decrease of amplitude, lasting at least 
30 min. Oral administration had a longer latency time 
and a less marked effect on uterine motility. Pharma­
cokinetic data, such as the maximum plasma concentra­
tion (Cmax), the time at which Cmax is reached (imax), 
and the half-life of absorption (T^abs) also showed 
large individual variation after oral administration (Fig,
4).
Oral administration of methylergometrine had an 
unpredictable and a late effect on uterine motility in the 
menstruating uterus probably due to an unpredictable 
bioavailability in contrast with the fast and predictable 
effect after intravenous administration.
The effects of an intravenous dose of methyler- 
gometrine on IUP without and with preceding oral 
methylergometrine maleate (0.5mg) 24 h before are 
strikingly different (Fig. 5). A strongly diminished effect 
of intravenous administered methylergometrine maleate 
24 h after oral administration suggests a long-lasting 
receptor blockade. It seemed as if the uterus was insen­
sitive to the methylergometrine maleate-dose. The first 
dose may affect and change the uterine receptors for 
methylergometrine maleate. Methylergometrine maleate 
probably blocks «-receptors in the inner layer, specifi­
cally affecting the basal tone of this layer [17-19].
3A, Clinical effects
Active management with oral ergometrine maleate 
0.4 mg was compared with expectant management for 
the control of bloodloss in the third stage of labour in 
women at low risk for PPH.
The design of the study was a three-arm randomized 
trial in which 0.4 mg ergometrine maleate (2 tablets of 
0 .2  mg) was set off against placebo, and both groups 
were compared with a standard oxytocin regimen of 5
IU.
It was calculated that a sample size of 140 per group 
was required to show a clinically relevant 30% reduc­
tion of bloodloss with an error rate of 0.05 (two-sided) 
and a power of 0.80. To allow comparison with the 
standard prophylactic regimen, a third group receiving 
intramuscular oxytocin was added. Formal randomisa­
tion was conducted in a 2 :2:1 design.
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Fig. 4. Effect o f methyl ergo rnetri ne maleate (ME) after intravenous (0.2 mg) [left] and oral (0.5 mg) [right] administration in one volunteer. At 
? =  0, ME was administered. Top-trace: Effect on intra-uterine pressure. Bottom'‘trace: Effect on frequency (F), basal tone (BT) and amplitude 
(A). The mean values of F, B and A during 30 min before drug administration were regarded as baseline values and set at 100%, the increase in 
a 5 min period was expressed as a percentage o f baseline value and plotted versus time after intravenous (0.2 mg) ME and oral (0.5 mg) ME 
administrations.
Of 367 parturients, 146 were randomized to er- 
gometrine maleate 0.4 mg, 143 to the placebo and 78 to 
intramuscular oxytocin. Compared with placebo, er- 
gometrine reduced bloodloss by 5% ( — 5%; confidence 
interval (Cl): — 20— h 13%)and oxytocin ( — 9%; Cl:
— 26- +  12%). Fig. 6 shows the estimates for the effect 
of the treatments on the amount of bloodloss.
4. Conclusions
Oral ergometrine has too little effect on bloodloss 
after childbirth in order to be a good alternative to 
parenteral prophylactic management.
Oral (methyl)ergometrine is not an alternative to 
parenteral prophylactic oxytocic drugs in the active
management of the third stage of labour. It is instable, 
its pharmacokinetic and pharmacodynamic properties 
are unpredictable and no clinical effect has been shown. 
All in all, the negative outcomes of the three studies on 
oral (methyl)ergometrine strengthen each other. To 
ameliorate a product’s stability seems unlogical, if the 
same product shows unfavourable pharmacokinetics. 
Even more so, because tablets do not show clinical 
effects. The research quest for easy alternatives, there­
fore, should be continued. If not, maternal mortality 
will remain a huge problem, costing 1500 lives a day.
The conclusion drawn from our research project is 
two-fold:
-  There is still no easy alternative to intramuscular 
oxytocin for the active management of the third 
stage of labour.
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Fig. 5. Effect of methylergometrine maleate (ME) after intravenous (0.2 mg) administration without preceding oral ME [left] and with preceding 
oral ME (0.5mg) [right] in one volunteer. At t — 0, ME was administered. For explanation of tracings, see Fig. 4.
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Blood loss (ml)
Fig. 6 . Effect of treatment on the amount of bloodloss postpartum 
(ml). Abbreviations; M, median; P, percentile (box~plot).
-  Because of unfavourable pharmaceutical and phar­
macokinetic properties oral (methyl)ergometrine 
should be excluded from the medication list.
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